Regional differences in the expression of nitric oxide synthase and specific receptors in the vascular tissues of control and diabetic rabbits: A pilot study

In Vivo

Volumn 21, Issue 6, 2007, Pages 1069-1074

  Alnaeb, M E ^a   Thompson, C S ^c   Seifalian, A M ^a,b   Hamilton, G ^a,b   Mikhailidis, D P ^a,c  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Atherosclerosis; Diabetes; Endothelin 1; Nitric oxide synthase; Serotonin

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; SEROTONIN; SEROTONIN RECEPTOR;

ABDOMINAL AORTA; ALLOXAN DIABETES MELLITUS; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; FEMORAL ARTERY; MALE; NONHUMAN; PILOT STUDY; PROTEIN EXPRESSION; RABBIT; RENAL ARTERY; TISSUE DISTRIBUTION; WESTERN BLOTTING;

EID: 37349048309     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Kinlay S and Ganz P: Relation between endothelial dysfunction and the acute coronary syndrome: implications for therapy. Am J Cardiol 86(8B): 10J-13J, 2000.
2. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW and Ganz P: Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 315(17): 1046-1051, 1986.
3. Creager MA, Luscher TF, Cosentino F and Beckman JA: diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I Circulation 108(12): 1527-1532, 2003.
4. De Vriese AS, Verbeuren TJ, Van de V, Lameire NH and Vanhoutte PM: Endothelial dysfunction in diabetes. Br J Pharmacol 130(5): 963-974, 2000.
5. Kugiyama K, Yasue H, Okumura K, Ogawa H, Fujimoto K, Nakao K, Yoshimura M, Motoyama T, Inobe Y and Kawano H: Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation 94(3): 266-271, 1996.
6. Furlong B, Henderson AH, Lewis MJ and Smith JA: Endothelium-derived relaxing factor inhibits in vitro platelet aggregation. Br J Pharmacol 90(4): 687-692, 1987.
7. Yao SK, Ober JC, Krishnaswami A, Ferguson JJ, Anderson HV, Golino P, Buja LM and Willerson JT: Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries. Circulation 86(4): 1302-1309, 1992.
8. Radomski MW, Palmer RM and Moncada S: Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 8567: 1057-1058, 1987.
9. Kubes P, Suzuki M and Granger DN: Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 88(11): 4651-4655, 1991.
10. Loscalzo J and Welch G: Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 38(2): 87-104, 1995.
11. Harrison DG: Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 100(9): 2153-2157, 1997.
12. Cooke JP and Dzau VJ: Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 48: 489-509, 1997.
13. Gryglewski RJ, Chlopicki S, Swies J and Niezabitowski P: Prostacyclin, nitric oxide, and atherosclerosis. Ann NY Acad Sci 748: 194-206, 1995.
14. Williams SB, Cusco JA, Roddy MA, Johnstone MT and Creager MA: Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 27(3): 567-574, 1996.
15. Tikkanen I and Fyhrquist F: Nitric oxide in hypertension and renal diseases. Ann Med 27(3): 353-357, 1995.
16. Winkles JA, Alberts GF, Brogi E and Libby P: Endothelin-1 and endothelin receptor mrna expression in normal and atherosclerotic human arteries. Biochem Biophys Res Commun 191(3): 1081-1088, 1993.
17. Zeiher AM, Goebel H, Schachinger V and Ihling C: Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. a clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation 91(4): 941-947, 1995.
18. Kelly JJ and Whitworth JA: Endothelin-1 as a mediator in cardiovascular disease. Clin Exp Pharmacol Physiol 26(2): 158-161, 1999.
19. Gensini GF, Conti AA and Prisco D: Endothelins: an overview of recent achievements. Ann Ital Med Int 13(2): 88-92, 1998.
20. Haynes WG, Strachan FE and Webb DJ: Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation 92(3): 357-363, 1995.
21. Cardillo C, Kilcoyne CM, Waclawiw M, Cannon RO III and Panza JA: Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 33(2): 753-758, 1999.
22. Masaki T, Vane JR and Vanhoutte PM: International union of pharmacology nomenclature of endothelin receptors. Pharmacol Rev 46(2): 137-142, 1994.
23. Miyauchi T and Masaki T: Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 61: 391-415, 1999.
24. Rebuffat P, Malendowicz LK, Neri G and Nussdorfer GG: Endothelin-1[1-31] acts as a selective eta-receptor agonist in the rat adrenal cortex. Histol Histopathol 16(2): 535-540, 2001.
25. Mazzocchi G, Rossi GP, Malendowicz LK, Champion HC and Nussdorfer GG: Endothelin-1[1-31], acting as an eta-receptor selective agonist, stimulates proliferation of cultured rat zona glomerulosa cells. FEBS Lett 487(2): 194-198, 2000.
26. Golino P, Crea F and Willerson JT: How to study the effects of platelet aggregation and thrombosis on coronary vasomotion and their clinical relevance. Ital Heart J 3(4): 220-225, 2002.
27. Kaumann AJ and Levy FO: 5-Hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther 111(3): 674-706, 2006.
28. Cheng KS, Mikhailidis DP, Hamilton G and Seifalian AM: A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors. Cardiovasc Res 54(3): 528-538, 2002.
29. Kawano H, Tsuji H, Nishimura H, Kimura S, Yano S, Ukimura N, Kunieda Y, Yoshizumi M, Sugano T, Nakagawa K, Masuda H, Sawada S and Nakagawa M: Serotonin induces the expression of tissue factor and plasminogen activator inhibitor-1 in cultured rat aortic endothelial cells. Blood 97(6): 1697-1702, 2001.
30. Martin GR and Humphrey PP: Receptors for 5-hydroxytryptamine: current perspectives on classification and nomenclature. Neuropharmacology 33(3-4): 261-273, 1994.
31. Hoyer D, Hannon JP and Martin GR: Molecular, pharmacological and functional diversity of 5-ht receptors. pharmacol Biochem Behav 71(4): 533-554, 2002.
32. Ishizuka T, Saisu H, Suzuki T, Kirino Y and Abe T: Molecular cloning of synaphins/complexins, cytosolic proteins involved in transmitter release, in the electric organ of an electric ray (Narke Japonica). Neurosci Lett 232(2): 107-110, 1997..
33. Desjardins F and Balligand JL: Nitric oxide-dependent endothelial function and cardiovascular disease. Acta Clin Belg 61(6): 326-334, 2006.
34. Nakagawa T, Sato W, Glushakova O, Heinig M, Clarke T, Campbell-Thompson M, Yuzawa Y, Atkinson M.A, Johnson RJ and Croker B: Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol 18(2): 539-550, 2007.
35. Hopfner RL and Gopalakrishnan V: Endothelin: emerging role in diabetic vascular complications. Diabetologia 42(12): 1383-1394, 1999.
36. Arikawa E, Cheung C, Sekirov I, Battell ML, Yuen VG and McNeill JH: Effects of endothelin receptor blockade on hypervasoreactivity in streptozotocin-diabetic rats: vessel-specific involvement of thromboxane A2. Can J Physiol Pharmacol 84(8-9): 823-833, 2006.
37. Neuhofer W and Pittrow D: Role of endothelin and endothelin receptor antagonists in renal disease. Eur J Clin Invest 36(Suppl 3): 78-88, 2006.
38. Golino P, Piscione F, Willerson J T, Cappelli-Bigazzi M, Foeaccio A, Villari B, Indolfi C, Russolillo E, Condorelli M and Chiarielto M: Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl J Med 324(10): 641-648, 1991.
39. Vikenes K, Farstad M and Nordrehaug JE: Serotonin is associated with coronary artery disease and cardiac events. Circulation 100(5): 483-489, 1999.
40. Hara Y, Hirowatari Y, Yoshika M, Komiyama Y, Tsuka Y and Takahashi H: The ratio of plasma to whole-blood serotonin may be a novel marker of atherosclerotic cardiovascular disease J Lab Clin Med 144(1): 31-37, 2004.
41. Yusuf S, Al Saady N and Camm AJ: 5-Hydroxytryptamine and atrial fibrillation: how significant is this piece in the puzzle? J Cardiovasc Electrophysiol 14(2): 209-214, 2003.
42. Akin D and Gurdal H: Involvement of 5-HT1B and 5-HT1D receptors in sumatriptan mediated vasocontractile response in rabbit common carotid artery. Br J Pharmacol 136(2): 177-182, 2002.
43. van den Brock RW, MaassenVanDenBrink A, Mulder PG, Bogers AJ, Avezaat CJ, John GW and Saxena PR: Comparison of contractile responses to donitriptan and sumatriptan in the human middle meningeal and coronary arteries. Eur J Pharmacol 443(1-3): 125-132, 2002.
44. Ishine T, Bouchelet I, Hamel E and Lee TJ: Serotonin 5-HT (7) receptors mediate relaxation of porcine pial veins. Am J Physiol Heart Circ Physiol 278(3): H907-H912, 2000.
45. Golino P, Piscione F, Benedict CR, Anderson HV, Cappelli-Bigazzi M, Indolfi C, Condorelli M, Chiariello M and Willerson JT: Local effect of serotonin released during coronary angioplasty. N Engl J Med 330(8): 523-528, 1994.
46. Vikenes K, Farstad M and Nordrehaug JE: Serotonin is associated with coronary artery disease and cardiac events. Circulation 100(5): 483-489, 1999.
47. Oyadomari S, Gotoh T, Aoyagi K, Araki E, Shichiri M and Mori M: Coinduction of endothelial nitric oxide synthase and arginine recycling enzymes in aorta of diabetic rats. Nitric Oxide 5(3): 252-260, 2001.
48. Trachtenberg JD, Sun S, Choi ET, Callow AD and Ryan US: Effect of endothelin-1 infusion on the development of intimal hyperplasia after balloon catheter injury. J Cardiovasc Pharmacol 22(Suppl 8): S355-S359, 1993.
49. Douglas SA, Vickery-Clark L M, Louden C and Ohlstein EH: Selective ETA receptor antagonism with BQ-123 is insufficient to inhibit angioplasty induced neointima formation in the rat. Cardiovasc Res 29(5): 641-646, 1995.
50. Douglas SA, Vickery-Clark LM, Louden C, Elliott JD and Ohlstein EH: Endothelin receptor subtypes in the pathogenesis of angioplasty-induced neointima formation in the rat: a comparison of selective eta receptor antagonism and dual ETA/ETB receptor antagonism using BQ-123 and SB 209670. J Cardiovasc Pharmacol 26(Suppl 3): S186-S189, 1995.
51. Munter K and Kirchengast M: The role of endothelin receptor antagonists in cardiovascular pharmacotherapy. Expert Opin Emerg Drugs 6(1): 3-11, 2001.
52. Tahara A, Kohno M, Yanagi S, Itagane H, Toda I, Akioka K, Teragaki M, Yasuda M, Takeuchi K and Takeda T: Circulating immunoreactive endothelin in patients undergoing percutaneous transluminal coronary angioplasty. Metabolism 40(12): 1235-1237, 1991.
53. Wang X, Douglas SA, Louden C, Vickery-Clark LM, Feuerstein GZ and Ohlstein EH: Expression of endothelin-1, endothelin-3, endothelin-converting enzyme-1 and endothelin-A and endothelin-B receptor MRNA after angioplasty-induced neointimal formation in the rat. Circ Res 78(2): 322-328, 1996.
54. Dashwood MR, Timm M, Muddle JR, Ong AC, Tippins JR, Parker R, McManus D, Murday AJ, Madden BP and Kaski JC: Regional variations in endothelin-1 and its receptor subtypes in human coronary vasculature: pathophysiological implications in coronary disease. Endothelium 6(1): 61-70, 1998.
55. Haller H: Postprandial glucose and vascular disease. Diabet Med 14(Suppl 3): S50-S56, 1997.
56. Khan MA, Dashwood MR, Mumtaz FH, Thompson CS, Mikhailidis DP and Morgan RJ: Upregulation of endothelin A receptor sites in the rabbit diabetic kidney: potential relevance to the early pathogenesis of diabetic nephropathy. Nephron 83(3): 261-267, 1999.
57. Alnaeb ME, Alobaid N, Seifalian AM, Mikhailidis DP and Hamilton G: Statins and peripheral arterial disease: potential mechanisms and clinical benefits. Ann Vasc Surg 20(5): 696-705, 2006.
58. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI and Elisaf M: The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. a subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 57(7): 728-734, 2004.
59. Athyros VG, Elisaf M, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, Milionis HJ and Mikhailidis DP: Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the Greek atorvastatin and coronary-heart-disease evaluation (GREACE) study. Am J Kidney Dis 43(4): 589-599, 2004.